TJ-M2010-5|cas:1357471-57-8|西域试剂

TJ-M2010-5,99.25%

产品编号：Bellancom-139397| CAS NO：1357471-57-8| 分子式：C₂₃H₂₆N₄OS| 分子量：406.54

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-139397	￥900.00	杭州北京（现货）
Bellancom-139397	￥1400.00	杭州北京（现货）
Bellancom-139397	￥2900.00	杭州北京（现货）
Bellancom-139397	￥4500.00	杭州北京（现货）
Bellancom-139397	￥6900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TJ-M2010-5

产品介绍

TJ-M2010-5 是一种 MyD88 抑制剂，可与 MyD88 的 TIR 结构域结合以干扰其同源二聚化和 TLR/MyD88 信号通路。TJ-M2010-5 可用于心肌缺血/再灌注损伤（MIRI）的研究。

生物活性

TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI).

体外研究

TJ-M2010-5 (40 µM) inhibits MyD88 homodimerization in transfected HEK293 cells in a concentration-dependent manner and suppresses MyD88 signaling in LPS (100 ng/mL)-responsive RAW 264.7 cells in vitro.
TJ-M2010-5 (5-30 μM) prevents B cell proliferation and induces B cells apoptosis after stimulation with R848 (500 ng/mL).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Purified B cells
Concentration:	0 μM, 5 μM, 10 μM, 20 μM and 30 μM
Incubation Time:	48 hours
Result:	Inhibited the viability of B cells with or without the stimulation of CD40L.

体内研究
(In Vivo)

TJ-M2010-5 treatment statistically significantly reduces AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, results in 0% mortality of treated mice, decreases cell proliferation, and increased apoptosis in colon tissue in a 10-week CAC mouse model.
TJ-M2010-5 statistically significantly decreases TNF-α, IL-6, G-CSF, MIP-1β, IL-11, IL-17A, IL-22, and IL-23 serum concentrations in mice at both two and seven weeks postinduction, as well as TGF-β1 serum levels at seven weeks postinduction.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BalB/c mice (6–8 weeks old)
Dosage:	50 mg/kg
Administration:	Treated i.p. daily beginning two days before the first dextran sodium sulfate (DSS) administration throughout a 10-week observation period.
Result:	Significantly prevented inflammation/CAC-related body weight loss and mortality (0% vs 53% in the control group).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BalB/c mice (6–8 weeks old)
Dosage:	50 mg/kg
Administration:	Treated i.p. daily beginning two days before the first dextran sodium sulfate (DSS) administration throughout a 10-week observation period.
Result:	Significantly prevented inflammation/CAC-related body weight loss and mortality (0% vs 53% in the control group).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BalB/c mice (6–8 weeks old)
Dosage:	50 mg/kg
Administration:	Treated i.p. daily beginning two days before the first dextran sodium sulfate (DSS) administration throughout a 10-week observation period.
Result:	Significantly prevented inflammation/CAC-related body weight loss and mortality (0% vs 53% in the control group).

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (245.98 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4598 mL	12.2989 mL	24.5978 mL
5 mM	0.4920 mL	2.4598 mL	4.9196 mL
10 mM	0.2460 mL	1.2299 mL	2.4598 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.15 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (6.15 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (6.15 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明